Identification of Active Chemotherapy Regimens in Advanced Biliary Tract Carcinoma: A Review of Chemotherapy Trials in the past Two Decades

References

• Ciombor KK , GoffLW. Current therapy and future directions in biliary tract malignancies. Curr. Treat. Options Oncol.14(3), 337–349 (2013).
   PubMed Web of Science ®Google Scholar
• Siegel R , NaishadhamD, JemalA. Cancer statistics 2013. CA Cancer J. Clin.63(1), 11–30 (2013).
   PubMed Web of Science ®Google Scholar
• Shaib YH , DavilaJA, McglynnK, El-SeragHB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?J. Hepatol.40(3), 472–477 (2004).
   PubMed Web of Science ®Google Scholar
• Siegel R , MaJ, ZouZ, JemalA. Cancer statistics 2014. CA Cancer J. Clin.64(1), 9–29 (2014).
   PubMed Web of Science ®Google Scholar
• Deoliveira ML , CunninghamSC, CameronJLet al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg.245(5), 755–762 (2007).
   PubMed Web of Science ®Google Scholar
• De Groen PC , GoresGJ, LarussoNF, GundersonLL, NagorneyDM. Biliary tract cancers. N. Engl. J. Med.341(18), 1368–1378 (1999).
   PubMed Web of Science ®Google Scholar
• Perpetuo MD , ValdiviesoM, HeilbrunLK, NelsonRS, ConnorT, BodeyGP. Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer42(1), 330–335 (1978).
   PubMed Web of Science ®Google Scholar
• Sharma A , DwaryAD, MohantiBKet al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J. Clin. Oncol.28(30), 4581–4586 (2010).
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd , MooreMJ, AndersenJet al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Valle J , WasanH, PalmerDHet al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Eckel F , SchmidRM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer96(6), 896–902 (2007).
   PubMed Web of Science ®Google Scholar
• Brandi G , DiGirdamoS, deRosaFet al. Second-line chemotherapy in patients with biliary tract cancer. ASCO Abstract J. Clin. Oncol.29(suppl e14590), (2011).
   Google Scholar
• Ducreux M , Van CutsemE, Van LaethemJLet al. A randomised Phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur. J. Cancer41(3), 398–403 (2005).
   PubMed Web of Science ®Google Scholar
• Furuse J , OkusakaT, BokuNet al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter Phase II study. Cancer Chemother. Pharmacol.62(5), 849–855 (2008).
   PubMed Web of Science ®Google Scholar
• Chen JS , YangTS, LinYC, JanYY. A Phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J. Clin. Oncol.33(7), 353–356 (2003).
   PubMed Web of Science ®Google Scholar
• Chen JS , JanYY, LinYC, WangHM, ChangWC, LiauCT. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs9(5), 393–397 (1998).
   PubMed Web of Science ®Google Scholar
• Choi CW , ChoiIK, SeoJHet al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am. J. Clin. Oncol.23(4), 425–428 (2000).
   PubMed Web of Science ®Google Scholar
• Ikeda M , OkusakaT, UenoH, MorizaneC, FuruseJ, IshiiH. A Phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J. Clin. Oncol.35(8), 439–443 (2005).
   PubMed Web of Science ®Google Scholar
• Malik IA , AzizZ. Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am. J. Clin. Oncol.26(2), 124–126 (2003).
   PubMed Web of Science ®Google Scholar
• Takashima A , MorizaneC, IshiiHet al. Randomized Phase II study of gemcitabine plus S-1 combination therapy vs S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). Jpn J. Clin. Oncol.40(12), 1189–1191 (2010).
   PubMed Web of Science ®Google Scholar
• Ueno H , OkusakaT, IkedaM, TakezakoY, MorizaneC. Phase II study of S-1 in patients with advanced biliary tract cancer. Br. J. Cancer91(10), 1769–1774 (2004).
   PubMed Web of Science ®Google Scholar
• Kang MEA . Randomized Phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma. ASCO Abstract J. Clin. Oncol.28(15S), 4029 (2010).
   PubMedGoogle Scholar
• Kobayashi K , TsujiA, MoritaS, HorimiT, ShirasakaT, KanematsuT. A Phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer6, 121 (2006).
   PubMed Web of Science ®Google Scholar
• Taieb J , MitryE, BoigeVet al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann. Oncol.13(8), 1192–1196 (2002).
   PubMed Web of Science ®Google Scholar
• Nehls O , KlumpB, ArkenauHTet al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective Phase II trial. Br. J. Cancer87(7), 702–704 (2002).
   PubMed Web of Science ®Google Scholar
• Lee SEA . Oxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer. ASCO Abstract J. Clin Oncol.29(Suppl. 15), 4106 (2011).
   Web of Science ®Google Scholar
• Hong YS , LeeJ, LeeSCet al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother. Pharmacol.60(3), 321–328 (2007).
   PubMed Web of Science ®Google Scholar
• Kim TW , ChangHM, KangHJet al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann. Oncol.14(7), 1115–1120 (2003).
   PubMed Web of Science ®Google Scholar
• Nehls O , OettleH, HartmannJTet al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre Phase II trial. Br. J. Cancer98(2), 309–315 (2008).
   PubMed Web of Science ®Google Scholar
• Kim YJ , ImSA, KimHGet al. A Phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann. Oncol.19(1), 99–103 (2008).
   PubMed Web of Science ®Google Scholar
• Oh SEA . Phase II trial of S-1 in combination with oxaliplain in previously untreated patients with recurrent or inoperable biliary tract cancer. ASCO Abstract J. Clin. Oncol.26(15S), 15611 (2008).
   Google Scholar
• Morizane C , OkadaS, OkusakaT, UenoH, SaishoT. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology64(4), 475–476 (2003).
   PubMed Web of Science ®Google Scholar
• Takezako Y , OkusakaT, UenoH, IkedaM, MorizaneC, NajimaM. Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC). Hepatogastroenterology55(85), 1380–1384 (2008).
   PubMedGoogle Scholar
• Rao S , CunninghamD, HawkinsREet al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared with epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br. J. Cancer92(9), 1650–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Lee MA , WooIS, KangJH, HongYS, LeeKS. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J. Cancer Res. Clin. Oncol.130(6), 346–350 (2004).
   PubMed Web of Science ®Google Scholar
• Park SH , ParkYH, LeeJNet al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer106(2), 361–365 (2006).
   PubMed Web of Science ®Google Scholar
• Park KH , ChoiIK, KimSJet al. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. Cancer103(11), 2338–2343 (2005).
   PubMed Web of Science ®Google Scholar
• Sasaki T , IsayamaH, NakaiYet al. A randomized Phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother. Pharmacol.71(4), 973–979 (2013).
   PubMed Web of Science ®Google Scholar
• Eng C , RamanathanRK, WongMKet al. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am. J. Clin Oncol.27(6), 565–569 (2004).
   PubMed Web of Science ®Google Scholar
• Gallardo JO , RubioB, FodorMet al. A Phase II study of gemcitabine in gallbladder carcinoma. Ann. Oncol.12(10), 1403–1406 (2001).
   PubMed Web of Science ®Google Scholar
• Okusaka T , IshiiH, FunakoshiAet al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother. Pharmacol.57(5), 647–653 (2006).
   PubMed Web of Science ®Google Scholar
• Park JS , OhSY, KimSHet al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a Phase II study. Jpn J. Clin. Oncol.35(2), 68–73 (2005).
   PubMed Web of Science ®Google Scholar
• Penz M , KornekGV, RadererMet al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann. Oncol.12(2), 183–186 (2001).
   PubMed Web of Science ®Google Scholar
• Tsavaris N , KosmasC, GouverisPet al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest. New Drugs.22(2), 193–198 (2004).
   PubMed Web of Science ®Google Scholar
• Lin MH , ChenJS, ChenHH, SuWC. A Phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy49(3), 154–158 (2003).
   PubMed Web of Science ®Google Scholar
• Von Delius S , LerschC, Schulte-FrohlindeE, MayrM, SchmidRM, EckelF. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer5, 61 (2005).
   PubMed Web of Science ®Google Scholar
• Mahfouf H . Chemotherapy using gemcitabine plus cisplatin in locally in stage III and IV gallbladder and biliary tract. ASCO Abstract J. Clin. Oncol.28(15S), e14654 (2010).
   Google Scholar
• Meyerhardt JA , ZhuAX, StuartKet al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig. Dis. Sci.53(2), 564–570 (2008).
   PubMed Web of Science ®Google Scholar
• Thongprasert S , NapapanS, CharoentumC, MoonprakanS. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann. Oncol.16(2), 279–281 (2005).
   PubMed Web of Science ®Google Scholar
• Doval DC , SekhonJS, GuptaSKet al. A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br. J. Cancer90(8), 1516–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Lee GW , KangJH, KimHG, LeeJS, LeeJS, JangJS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am. J. Clin. Oncol.29(2), 127–131 (2006).
   PubMed Web of Science ®Google Scholar
• Giuliani F . Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a mulitcenter Phase II study of the GOIM. Ann. Oncol.17(Suppl. 7), vii73 (2006).
   PubMed Web of Science ®Google Scholar
• Kim ST , ParkJO, LeeJet al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer106(6), 1339–1346 (2006).
   PubMed Web of Science ®Google Scholar
• Lee J , ParkSH, ChangHMet al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol.13(2), 181–188 (2012).
   PubMed Web of Science ®Google Scholar
• Jang JS , LimHY, HwangIGet al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group Phase II trial. Cancer Chemother. Pharmacol.65(4), 641–647 (2010).
   PubMed Web of Science ®Google Scholar
• Andre T , Reyes-VidalJM, FartouxLet al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a Phase II study. Br. J. Cancer99(6), 862–867 (2008).
   PubMed Web of Science ®Google Scholar
• Harder J , RieckenB, KummerOet al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br. J. Cancer95(7), 848–852 (2006).
   PubMed Web of Science ®Google Scholar
• Kim HEA . Phase II study of gemcitabine and oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. ASCO Abstract J. Clin Oncol.26(15S), 15536 (2009).
   Google Scholar
• Sharma A , MohantiB, RainaVet al. A Phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother. Pharmacol.65(3), 497–502 (2010).
   PubMed Web of Science ®Google Scholar
• Lim H . Phase III study of gemcitabine/oxaliplatin GEMOX with or without erlotinib in unresectable, metastatic biliary tract carcinoma. ASCO Abstract J. Clin Oncol.29(18 S), LBA4032 (2011).
   Web of Science ®Google Scholar
• Phelip JEA . Multicentric Phase II randomized trial comparing chemoradiation with 5-fluorouracil, cisplatin and 50 GY versus chemotherapy alone with gemcitabine plus oxaliplatin for locally advanced biliary tract cancer. Ann. Oncol.3(9S), 730P (2012).
   Google Scholar
• Uddin M . Phase II study of gemcitabine and oxaliplatin in unresectable gall bladder cancer. Ann. Oncol. Abstract21(S 8), 798 (2010).
   Google Scholar
• Verderame F , RussoA, Di LeoRet al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann. Oncol.17(Suppl. 7), vii68–72 (2006).
   PubMedGoogle Scholar
• Malka DEA . Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: final analysis of a randomized Phase II trial (BINGO). ASCO abstract J. Clin Oncol.30(15 S), 4032 (2012).
   Google Scholar
• Julka PK , PuriT, RathGK. A Phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary. Pancreat. Dis. Int.5(1), 110–114 (2006).
   PubMedGoogle Scholar
• Williams KJ , PicusJ, TrinkhausKet al. Gemcitabine with carboplatin for advanced biliary tract cancers: a Phase II single institution study. HPB (Oxford)12(6), 418–426 (2010).
   PubMed Web of Science ®Google Scholar
• Cho JY , NamJS, ParkMSet al. A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. Yonsei. Med. J.46(4), 526–531 (2005).
   PubMed Web of Science ®Google Scholar
• Alberts SR , Al-KhatibH, MahoneyMRet al. Gemcitabine, 5-fluorouracil, and leucovorin in advancedbiliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group Phase II trial. Cancer103(1), 111–118 (2005).
   PubMed Web of Science ®Google Scholar
• Iqbal S , RankinC, LenzHJet al. A Phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother. Pharmacol.68(6), 1595–1602 (2011).
   PubMed Web of Science ®Google Scholar
• Kanai M , YoshimuraK, TsumuraTet al. A multi-institution Phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother. Pharmacol.67(6), 1429–1434 (2011).
   PubMed Web of Science ®Google Scholar
• Cho JY , PaikYH, ChangYSet al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer104(12), 2753–2758 (2005).
   PubMed Web of Science ®Google Scholar
• Bae BSE . Phase II study of fixed dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: DAEGU GYEOUNGBUK oncology group. Ann. Oncol. Abstract: 21, Suppl. 8, (2010).
   PubMedGoogle Scholar
• Hsu C , ShenYC, YangCHet al. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br. J. Cancer90(9), 1715–1719 (2004).
   PubMed Web of Science ®Google Scholar
• Iyer RV , GibbsJ, KuvshinoffBet al. A Phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann. Surg. Oncol.14(11), 3202–3209 (2007).
   PubMed Web of Science ®Google Scholar
• Knox JJ , HedleyD, OzaAet al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a Phase II trial. J. Clin. Oncol.23(10), 2332–2338 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SEA . Fixed dose rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced biliary cancer. ASCO Abstract J. Clin. Oncol.27(15S), e15581 (2009).
   Google Scholar
• Nakamura K . A Phase II trial of oral S-1 combined with gemcitabine in patients with unresectable biliary tract cancer. ASCO Abstract J. Clin. Oncol.27(15S), e15527 (2009).
   Google Scholar
• Riechelmann RP , TownsleyCA, ChinSN, PondGR, KnoxJJ. Expanded Phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer110(6), 1307–1312 (2007).
   PubMed Web of Science ®Google Scholar
• Santini D . Fixed dose rate FDR gemcitabine and capecitabine in patients with metastatic biliary tract cancer: Final results of Phase II trial. ASCO Abstract J. Clin. Oncol.27(15S), e15510 (2009).
   Google Scholar
• Sasaki T . Multicenter Phase II study of gemcitabine plus S-1 in patients with advanced biliary tract cancer. ASCO Abstract J. Clin. Oncol.27(15S), e15516 (2009).
   Google Scholar
• Ueno MEA . Randomized Phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results for the Japan Clinicla Oncology Group study. ASCO Abstract J. Clin. Oncol.30(Suppl. 15), 4031 (2012).
   Google Scholar
• Wagner AD , Buechner-SteudelP, MoehlerMet al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre Phase-II trials. Br. J. Cancer101(11), 1846–1852 (2009).
   PubMed Web of Science ®Google Scholar
• Alberts SR , SandeJR, FosterNRet al. Pemetrexed and gemcitabine for biliary tract andgallbladder carcinomas: a North Central CancerTreatment Group (NCCTG) Phase I and II Trial, N9943. J. Gastrointest. Cancer38(2-4), 87–94 (2007).
   PubMedGoogle Scholar
• Chung MJ , KimYJ, ParkJYet al. Prospective Phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy57(3), 236–243 (2011).
   PubMed Web of Science ®Google Scholar
• Karachaliou N , PolyzosA, KentepozidisNet al. A multicenter Phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Oncology78(5–6), 356–360 (2010).
   PubMed Web of Science ®Google Scholar
• Feisthammel J , SchoppmeyerK, MossnerJ, SchulzeM, CacaK, WiedmannM. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter Phase II trial. Am. J. Clin. Oncol.30(3), 319–324 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg RM . N9741: a Phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer. Clin. Colorectal Cancer2(2), 81 (2002).
   PubMedGoogle Scholar
• Findlay M , CunninghamD, NormanAet al. A Phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol.5(7), 609–616 (1994).
   PubMed Web of Science ®Google Scholar
• Cunningham D , StarlingN, RaoSet al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med.358(1), 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , ErvinT, ArenaFPet al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med.369(18), 1691–1703 (2013).
   PubMed Web of Science ®Google Scholar
• Jensen LH , LarsenO. Systemic treatment of biliary tract cancer. Ugeskr. Laeger175(42), 2478–2481 (2013).
   PubMedGoogle Scholar
• Glimelius B , HoffmanK, SjodenPOet al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol.7(6), 593–600 (1996).
   PubMed Web of Science ®Google Scholar
• Yonemoto N , FuruseJ, OkusakaTet al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J. Clin. Oncol.37(11), 843–851 (2007).
   PubMed Web of Science ®Google Scholar
• Sasaki T , IsayamaH, NakaiY, KoikeK. Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean. J. Intern. Med.28(5), 515–524 (2013).
   PubMed Web of Science ®Google Scholar
• Cereda S , BelliC, RognoneA, MazzaE, ReniM. Second-line therapy in advanced biliary tract cancer: what should be the standard?Crit. Rev. Oncol. Hematol.88(2), 368–374 (2013).
   PubMed Web of Science ®Google Scholar
• Walter T , HorganAM, McnamaraMet al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur. J. Cancer49(2), 329–335 (2013).
   PubMed Web of Science ®Google Scholar